High-Utilizing Patients: Where Are the Savings?
If 1% of patients account for 21% of total health care spending, why is there so little proof of ROI from giving them appropriate care?
Bundled payments, big data, and advances in personalized medicine will change the way primary care physicians and others practice
Provider groups put money into systems that heighten the focus on measuring performance
Qsymia and Belviq can slow the progression of diabetes, but side effects and retail cost of about $200 per month are obstacles to formulary placement
Emerging data show impressive results on glycemic control, but what about long-term results, safety, and high maintenance costs?
Departments
Consumers expect reasonable premiums and copayments but give health plans grief over a proven cost-control method. How soon we forget.
Management tactic borrowed from traditional pharmacy
Twenty-five years ago we had not even identified the virus that was neither type A nor type B. Now we have slowed its spread and can cure it, at considerable cost.
News & Commentary
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.